Previous 10 | Next 10 |
2023-12-11 16:42:25 ET French drugmaker Sanofi ( NASDAQ: SNY ) on Monday said it would terminate a previously announced licensing deal with U.S. biotech Maze Therapeutics for an investigational Pompe disease treatment candidate, after the agreement was challenged by the U.S. Fe...
2023-12-07 23:57:14 ET Summary MoonLake Therapeutics is a clinical-stage biopharmaceutical company developing nanobody-based therapies for inflammatory diseases. Their lead product candidate, Sonelokimab, has shown best-in-class potential in treating Hidradenitis suppurativa and P...
2023-12-07 07:36:32 ET Vanda Pharmaceuticals ( NASDAQ: VNDA ) has acquired the U.S. and Canadian rights to relapsing multiple sclerosis drug Ponvory (ponesimod) from J&J ( NYSE: JNJ ) unit Actelion for $100M. Approved by FDA and Health Canada, Ponvory is indicate...
2023-12-07 05:36:06 ET Sanofi ( NASDAQ: SNY ) said on Thursday its multiple myeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial. The drug is currently indicated for use in a combination therapy for previously-treated relapsed or refractory mult...
2023-12-06 04:37:12 ET More on Merck KGaA Merck KGaA (MKGAF) Q3 2023 Earnings Call Transcript Merck KGaA: Company With A Potential Upside Exscientia climbs as Merck KGaA joins AI drug discovery Historical earnings data for Merck KGaA Dividend scorecar...
2023-12-05 22:50:05 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-12-05 16:42:48 ET More on IGM Biosciences IGM Biosciences: What Causes The Very High Short Interest In This Ticker IGM Biosciences GAAP EPS of -$1.04 beats by $0.21, revenue of $0.51M misses by $0.34M IGM Biosciences Chief Commercial Officer discloses sale of 93...
2023-12-04 07:05:00 ET Summary Here are three undervalued stocks with promising growth potential and high-quality A-rated balance sheets. It's just one of three incredible opportunities that combine to create a 16% annual return potential for the next decade, 350%, almost 3X more ...
2023-12-01 14:19:23 ET More on Novo Nordisk Novo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation Novo Nordisk: Massive Reality Check Awaits Greedy Investors Novo Nordisk: Healthy Gains Ahead, EPS Growth Seen, Technical Strength Cantor bullish on ...
2023-11-30 08:30:00 ET Many investing trends and fads come and go, but the need for innovative medicines isn't one of them. Drugs, especially those that treat potentially life-threatening conditions, are always in demand. That's why companies that develop and market medicines can remain rel...
News, Short Squeeze, Breakout and More Instantly...
Sanofi ships U.S. influenza vaccines for the 2024/25 season PR Newswire Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
2024-07-09 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...